<DOC>
	<DOCNO>NCT01376323</DOCNO>
	<brief_summary>The aim combine , two part study evaluate safety glucose lowering effect GSK256073 administer diabetic subject 12 week .</brief_summary>
	<brief_title>A Study GSK256073 Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin</brief_title>
	<detailed_description>The study conduct center Europe United States . The study conduct two part . Part A ( n = 90 subject ) provide preliminary evaluation 12 week treatment . Initiation part B ( n = 210 additional subject ) dependent result observe part A . The emerge data part A use guide selection dose Part B . Up 8 dose level GSK256073 may include part B . The emerge exposure response relationship part A interim analysis use guide dose selection . Each subject enrol study undergo screen procedure , 2 week placebo run-in period , baseline assessment , randomization , twelve week treatment period , 2 week follow-up period . Following completion baseline visit randomization study , subject return clinic safety efficacy assessment Weeks 3 , 6 , 9 , 12 . A subject 's total participation study last approximately 20 week . Subjects continue current prescribed regimen metformin ( glucophage ) monotherapy monitor fast blood glucose level daily use glucometer .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>A diagnosis T2DM determine responsible physician base medical evaluation include medical history , physical examination , laboratory test , onset least 6 month prior Screening . Subjects may enter stable hypertension dyslipidemia therapy . Subjects condition except noted Exclusion criterion may include investigator GSK medical monitor agree condition unlikely introduce additional risk factor interfere study procedure HbA1c level great equal 7.0 % less equal 9.5 % Screening On monotherapy metformin time screening , maximum tolerate dose great equal 1000 mg least 2 month prior dose . Fasting plasma glucose level less 13.3 mmol/L ( 240 mg/dL ) Screening Male female 20 70 year age , inclusive , time signing informed consent Fasting Triglycerides low 4.52 mmol/L ( 400 mg/dL ) A female subject able participate nonchild bear potential Male subject must agree use one contraception method list protocol . This criterion must follow time first dose study medication 3 day last dose study medication Overweight BMI great equal 25 kg/m2 nonAsian Indians great equal 24 kg/m2 AsianIndian , less 40 kg/m2 The subject capable give write informed consent , include compliance requirement restriction list consent form Subjects France eligible affiliate beneficiary social security category Subjects country must meet local and/or countryspecific requirement registration reimbursement , applicable Requiring insulin therapy use combination oral antidiabetic medication use monotherapy metformin within 3 month prior screen Past present disease ( type 2 diabetes mellitus ) opinion Investigator may affect outcome study A positive prestudy Hepatitis B surface antigen , positive Hepatitis C result within 3 month screen Renal impairment define calculated GFR le 60 mL/min Any concurrent serious illness ( e.g. , severe COPD , history malignancy skin cancer within 5 year initial diagnosis evidence recurrence ) may interfere subject complete study Laboratory value define per protocol ECG criterion define per protocol Systolic blood pressure great 160 mmHg , diastolic blood pressure great 100 mmHg Screening History uric acid kidney stone , treat drug hyperuricemia include Allopurinol Probenecid History peptic ulcer disease ( PUD ) and/or gastrointestinal bleeding within 12 month prior screen Use certain blood pressure medication certain medication renally excrete defined per protocol History myopathy CPK value great 3 time upper limit normal screen The subject participate clinical trial receive investigational product within 30 day 5 halflives twice biological effect ( whichever longer ) Exposure four new chemical entity within 12 month prior first dose day Any change diet , exercise habit smoke status within six week prior screen . Any subject refrain smoking unit must exclude History sensitivity study medication , include sitagliptin metformin , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation The subject positive prestudy drug screen History regular alcohol consumption within 6 month study define per protocol Where participation study would result donation blood blood product excess 500 mL within 56 day period Pregnant female determine positive serum and/or urine hCG test screen prior dose Lactating female Subjects unwilling unable follow procedure outline protocol Subject mentally legally incapacitate</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Dose Ranging</keyword>
	<keyword>Efficacy</keyword>
</DOC>